In simple terms, risk is the possibility of something bad happening. It’s the uncertainty around the consequences of an activity with respect to something that we value.
USP’s success in its mission to improve global public health through creation of standards and related programs depends in large part on the work of volunteers.
Access to quality raw materials and increased stakeholder collaboration are needed to help ensure availability of monoclonal antibody (mAb) treatments for COVID-19 in low- and middle-income countries (LMICs).
The presence of objectionable levels of chemical impurities in pharmaceuticals can have serious public health impacts.
During the COVID-19 pandemic, we have become acutely aware of how precious time is and the potential repercussions of delays or inefficiencies.
As African nations begin to ease lockdown restrictions, health systems are bracing to prevent the novel coronavirus from spreading rapidly through their populations.
Antimicrobial resistance (AMR) is a global health challenge which can undermine standard treatments and procedures on which we have come to rely.
For nearly 200 years, USP’s public standards have served to establish a common foundation upon which the quality of medicines can be evaluated, building trust in the healthcare system and enabling innovation to thrive. During that time, medicine has evolved tremendously.